With a Market Worth Hundreds of Billions, When Will Peptide Drugs Become the Next Blockbuster? | BlueRun Ventures × VBData Forum Now Open for Registration
Where Does the Hot Peptide Market Go From Here?
Peptide drugs have become a major focus of new drug research thanks to their well-defined targets and favorable drug-like properties. As structural modification and chemical engineering methods continue to evolve — alongside the development of new targets, expansion into new indications, and formulation optimization — the market for peptide drugs is poised for significant growth.
By 2025, China's peptide drug market is projected to exceed RMB 100 billion. Meanwhile, surging sales of blockbuster GLP-1 drugs have put the global peptide drug supply chain into an upward cycle, fueling rapid growth among CDMOs, raw material suppliers, and consumables companies.
On May 8, BlueRun Ventures will co-host the Peptide Drugs and Industry Chain Innovation Development Forum with ArteryNet, VB100, Eggshell Research Institute, and ArteryOrange to explore where peptide drugs are headed in this trillion-scale market. The forum will run from 13:30 to 16:40 at the Beijing Ren Yichuang International Convention and Exhibition Center.
How can CDMO innovation accelerate peptide drug development? What are the emerging directions for peptide synthesis consumables and raw materials? How can companies break through the race to the bottom and build globally competitive, differentiated GLP-1 products? If these questions resonate with you, we welcome you to join us on-site.
To attend, scan the QR code in the image to register
A small perk
Share this article to your Moments, screenshot it, and send it to our official account along with your name, phone number, and employer for registration — you'll receive a complimentary ticket from BlueRun Ventures. Limited quantity, first come first served!
▶ More Content ◀
Founded in 2005, BlueRun Ventures is a venture capital firm focused on early-stage startups.
The firm currently manages over RMB 15 billion in assets, making it one of China's largest early-stage funds. It invests primarily at the Pre-A and Series A stages across technology, consumer, and healthcare sectors, with more than 200 portfolio companies to date, including Li Auto, Waterdrop, QingCloud, Guazi.com, Qudian, Ganji.com, Energy Monster, Gaussian Robotics, Songguo, Yuntu Semiconductor, Machenike, Cloud Saint Intelligence, Anxin Wangdun, and BioMap.
BlueRun Ventures has been ranked #1 on Zero2IPO's "China Top 30 Early-Stage Investment Institutions" and ChinaVenture's "China Best Early-Stage Venture Capital Firms TOP30," and was named among Preqin's Top 10 VC fund managers globally for consistent high returns.
The firm has also received multiple honors from Forbes China, 36Kr, Cyzone, Caixin Media, CBNweekly, Jiemian, and other media outlets, including "China's Best Early-Stage Firm of the Year," "China's Top Venture Capital Firm," "Most Entrepreneur-Friendly Early-Stage Firm of the Year," and "Most Influential Early-Stage Firm of the Year."